Bellicum raises $55mm through oversubscribed Series C round

Bellicum Pharmaceuticals Inc. (cell-based immunotherapies) raised $55mm through an oversubscribed Series C round. New investors RA Capital Management, Perceptive Advisors, Jennison Associates LLC, Sabby Capital, Ridgeback Capital Management, venBio Select, Redmile Group, LLC, AJU IB Investment, and three others participated, along with all of the company’s major returning investors including AVG Ventures and Remeditex Ventures. Jefferies & Co. was the placement agent. Some of the proceeds will fund development of BPX501, a Phase I/II controlled donor T-cell immunotherapy used in hematopoietic stem cell transplant in patients with leukemia or lymphoma, and also in cases of nonmalignant genetic diseases including severe combined immune deficiency, beta-thalassemia, sickle cell disease, and Fanconi anemia. Including the current round, Bellicum has raised $107mm since its 2004 inception.